Price: $83.6600
$0.09
0.108%
|
Day's High:
| $83.94
| Week Perf:
| -2.43 %
|
Day's Low: |
$ 83.63 |
30 Day Perf: |
-1.25 % |
Volume (M): |
181 |
52 Wk High: |
$ 92.02 |
Volume (M$): |
$ 15,166 |
52 Wk Avg: |
$82.62 |
Open: |
$83.44 |
52 Wk Low: |
$68.84 |
|
|
Market Capitalization (Millions $) |
111,410 |
Shares
Outstanding (Millions) |
1,332 |
Employees |
95,000 |
Revenues (TTM) (Millions $) |
32,319 |
Net Income (TTM) (Millions $) |
4,234 |
Cash Flow (TTM) (Millions $) |
-2,899 |
Capital Exp. (TTM) (Millions $) |
1,539 |
Medtronic Plc
Medtronic is a world leading medical technology company, providing lifelong solutions
for people with chronic disease. We are committed to offering market-leading therapies
worldwide to restore patients to fuller, healthier lives. With beginnings in the
treatment of heart disease, we have expanded well beyond our historical core business
and today provide a wide range of products and therapies that help solve many
challenging, life-limiting medical conditions. We hold market-leading positions
in almost all of the major markets in which we compete.
Company Address: 20 On Hatch, Lower Hatch Street Dublin 2 0
Company Phone Number: 438-1700 Stock Exchange / Ticker: NYSE MDT
|
|
Customers Net Income fell by |
MDT's Customers Net Profit Margin fell to |
-1.34 % |
2.96 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Medtronic Plc
Medtronic Plc, a global leader in healthcare technology, recently reported its third-quarter results for 2024. The company experienced a revenue growth of 4.685% to $8.09 billion compared to $7.73 billion in the same reporting season the previous year. This represents a solid performance, although it falls short of the 8.27% top-line improvement reported by its contemporaries in the Medical Equipment & Supplies sector. In terms of earnings per share (EPS), Medtronic Plc saw an increase of 7.61% to $0.99 from $0.92 in the prior year reporting season. The company's bottom-line also showed improvement, with net earnings of $1,337.000 million in the third quarter of 2024, an 8.79% increase from $1,229.000 million reported in the same period a year ago.
|
Products & Services
Published Mon, Jan 8 2024 5:38 PM UTC
FDA Approves Medtronic's Advanced Percept RC Neurostimulator with Exclusive BrainSense Technology: Revolutionizing Deep Brain StimulationIn a breakthrough development, the FDA has granted approval to Medtronic for its latest innovation - the Percept RC neurostimulator. Esteemed as the first and only deep brain stimulation system with sensing, directionality, and advanced pro...
|
Medtronic Plc
Medtronic Plc Shows Strong Financial Performance and Market Potential Medtronic Plc, a leading medical technology company, has recently announced its financial results for the period ending October 27, 2023. The company demonstrated impressive growth, with significant increases in income per share, revenue, and net income. One of the standout achievements for Medtronic Plc is the growth in income per share. Compared to the previous year, the company saw a remarkable 112.5% increase in income per share, from $0.32 to $0.68. Additionally, income per share advanced by 15.25% from the preceding reporting period, reaching $0.59 per share. This marked improvement reflects the company's ability to generate strong profits and create value for its shareholders.
|
Medtronic Plc
Investors in the stock market have been closely following the recent financial performance of Medtronic Plc, and there are some interesting developments to consider. Despite a decline in earnings per share (EPS), the company has managed to increase its revenue. In the span from May to July 28, 2023, Medtronic reported a revenue increase of 4.491% to an impressive $7.70 billion, compared to $7.37 billion in the same period the previous year. However, there was a decrease in income of -15.71% with an EPS of $0.59, compared to $0.70 in the same period the year before. This decline in income per share can be seen as a potential concern, but it is important to remember that Medtronic Plc had previously achieved a bottom line of $0.89 per share in the preceding financial reporting period.
|
Medtronic Plc
Financial News Report: Medtronic Plc Reports Mixed Earnings Results Medtronic Plc, a leading Medical Equipment & Supplies company, recently released its financial results for the most recent fiscal period, causing a stir in the market. The company reported contradictory figures, with revenue experiencing a notable increase while income and profits showed a significant decline. In comparison to the previous year, Medtronic Plc's revenue rose by 5.625% to $8.54 billion, indicating a positive trend. However, the income fell by -19.74% to $0.89 per share, down from $1.11 in the prior year reporting season. Additionally, net profits of $1,189.000 million in the financial time-frame ending April 28, 2023, fell by -20.36% from $1,493.000 million in the corresponding period a year before.
|
Per Share |
Current |
Earnings (TTM) |
3.15 $ |
Revenues (TTM) |
24.27 $
|
Cash Flow (TTM) |
- |
Cash |
6.25 $
|
Book Value |
39.04 $
|
Dividend (TTM) |
2.75 $ |
|
Per Share |
|
Earnings (TTM) |
3.15 $
|
Revenues (TTM) |
24.27 $ |
Cash Flow (TTM) |
- |
Cash |
6.25 $
|
Book Value |
39.04 $ |
Dividend (TTM) |
2.75 $ |
|
|
|
Cardiac Rhythm Management |
|
Segment |
|
|
of total Revenue |
DIABETES |
|
Segment |
|
|
of total Revenue |
Spinal & ENT |
|
Segment |
|
|
of total Revenue |
CARDIOVASCULAR |
|
Segment |
|
|
of total Revenue |
NEUROMODULATION |
|
Segment |
|
|
of total Revenue |
SURGICAL TECHNOLOGIES |
|
Segment |
|
|
of total Revenue |
Cardiac Vascular |
|
Segment |
|
|
of total Revenue |
Restorative Therapies |
|
Segment |
|
|
of total Revenue |
|
|
|